3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
2
CNS
2
Thoracic
1
Other hematologic neoplasm
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Pancreatic Neoplasms
2
Ovarian Neoplasms
2
Neoplasm Metastasis
2
Lung Neoplasms
2
Breast Neoplasms
2
Urinary Bladder Neoplasms
1
Thyroid Neoplasms
1
Stomach Neoplasms
1
Sarcoma
1
Prostatic Neoplasms
1
Neoplasms
1
Melanoma
1
Liver Neoplasms
1
Leukemia
1
Kidney Neoplasms
1
Glioblastoma
1
Esophageal Neoplasms
1
Disease
1
Colorectal Neoplasms
1
Colonic Neoplasms
1
Carcinoma, Bronchogenic
1
Interventions
pembrolizumab
13
Gemcitabine
12
Cyclophosphamide
10
Carboplatin
10
Specimen Handling
8
Magnetic Resonance Spectroscopy
8
Cisplatin
8
Docetaxel
7
X-Rays
6
Filgrastim
6
Doxorubicin
6
Biopsy
6
tislelizumab
5
Radiosurgery
5
Phantoms, Imaging
5
Paclitaxel
5
Nivolumab
5
Irinotecan
5
Bevacizumab
5
130-nm albumin-bound paclitaxel
5
spartalizumab
4
palbociclib
4
Thiotepa
4
Temozolomide
4
Radiotherapy
4
Nuclear Medicine Department, Hospital
4
Mesna
4
Ipilimumab
4
Imatinib Mesylate
4
Ifosfamide
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Sarcoma
×
Interleukin-15
×
Gastrointestinal
×
Clear all
NCT07410676
2026-02-18
EBNK-ST-001
Essen Biotech
Phase 1/2
Recruiting
83 enrolled